{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T14:44:37Z","timestamp":1793889877602,"version":"4.8.0"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,5]],"date-time":"2025-02-05T00:00:00Z","timestamp":1738713600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82425002"],"award-info":[{"award-number":["82425002"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82200250"],"award-info":[{"award-number":["82200250"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82270234"],"award-info":[{"award-number":["82270234"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82370223"],"award-info":[{"award-number":["82370223"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82130003"],"award-info":[{"award-number":["82130003"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008990","name":"Science and Technology Department of Zhejiang Province","doi-asserted-by":"publisher","award":["2023C03060"],"award-info":[{"award-number":["2023C03060"]}],"id":[{"id":"10.13039\/501100008990","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Advanced Research"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.jare.2025.02.006","type":"journal-article","created":{"date-parts":[[2025,2,11]],"date-time":"2025-02-11T19:10:22Z","timestamp":1739301022000},"page":"461-469","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Sequential allogeneic HSCT after CAR-T therapy for relapsed\/refractory acute lymphoblastic leukemia patients: A long-term follow-up result"],"prefix":"10.1016","volume":"78","author":[{"given":"Tingting","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yetian","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jimin","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingming","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Delin","family":"Kong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingjing","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shan","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pingnan","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruimin","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huijun","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanmin","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyu","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lizhen","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huarui","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yishan","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dawei","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiazhen","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simao","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guoqing","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex H.","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"He","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongxian","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.jare.2025.02.006_b0005","doi-asserted-by":"crossref","first-page":"589","DOI":"10.3324\/haematol.2009.014274","article-title":"Outcome after relapse of acute lymphoblastic leukemia in adult patients included in four consecutive risk-adapted trials by the PETHEMA Study Group","volume":"95","author":"Oriol","year":"2010","journal-title":"Haematologica"},{"key":"10.1016\/j.jare.2025.02.006_b0010","article-title":"The present and future for CAR-T cell therapy in adult B-cell ALL","author":"Roddie","year":"2024","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.jare.2025.02.006_b0015","doi-asserted-by":"crossref","DOI":"10.6004\/jnccn.2024.7065","article-title":"The role of CAR T-cell therapy in relapsed\/refractory adult B-ALL","volume":"22","author":"Othman","year":"2024","journal-title":"J Natl Compr Canc Netw"},{"issue":"5","key":"10.1016\/j.jare.2025.02.006_b0020","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1056\/NEJMoa1709919","article-title":"Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia","volume":"378","author":"Park","year":"2018","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.jare.2025.02.006_b0025","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1182\/bloodadvances.2020001466","article-title":"Efficacy and safety of anti-CD19 CAR T-cell therapy in 110 patients with B-cell acute lymphoblastic leukemia with high-risk features","volume":"4","author":"Zhang","year":"2020","journal-title":"Blood Adv"},{"issue":"15","key":"10.1016\/j.jare.2025.02.006_b0030","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1182\/blood-2018-11-883710","article-title":"Factors associated with durable EFS in adult B-cell ALL patients achieving MRD-negative CR after CD19 CAR T-cell therapy","volume":"133","author":"Hay","year":"2019","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.jare.2025.02.006_b0035","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/s13045-020-00873-7","article-title":"Pre-transplant MRD negativity predicts favorable outcomes of CAR-T therapy followed by haploidentical HSCT for relapsed\/refractory acute lymphoblastic leukemia: a multi-center retrospective study","volume":"13","author":"Zhao","year":"2020","journal-title":"J Hematol Oncol"},{"issue":"5","key":"10.1016\/j.jare.2025.02.006_b0040","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1111\/bjh.15086","article-title":"Pre- and post-transplant minimal residual disease predicts relapse occurrence in children with acute lymphoblastic leukaemia","volume":"180","author":"Lovisa","year":"2018","journal-title":"Br J Haematol"},{"issue":"7926","key":"10.1016\/j.jare.2025.02.006_b0045","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1038\/s41586-022-05140-y","article-title":"Non-viral, specifically targeted CAR-T cells achieve high safety and efficacy in B-NHL","volume":"609","author":"Zhang","year":"2022","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.jare.2025.02.006_b0050","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005701","article-title":"Safety and efficacy of autologous and allogeneic humanized CD19-targeted CAR-T cell therapy for patients with relapsed\/refractory B-ALL","volume":"11","author":"Song","year":"2023","journal-title":"J Immunother Cancer"},{"issue":"10","key":"10.1016\/j.jare.2025.02.006_b0055","doi-asserted-by":"crossref","first-page":"2764","DOI":"10.1158\/1078-0432.CCR-20-3863","article-title":"CRISPR\/Cas9-engineered universal CD19\/CD22 dual-targeted CAR-T cell therapy for relapsed\/refractory B-cell acute lymphoblastic leukemia","volume":"27","author":"Hu","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"17","key":"10.1016\/j.jare.2025.02.006_b0060","doi-asserted-by":"crossref","first-page":"2735","DOI":"10.1182\/blood-2014-04-571570","article-title":"T-cell-replete haploidentical HSCT with low-dose anti-T-lymphocyte globulin compared with matched sibling HSCT and unrelated HSCT","volume":"124","author":"Luo","year":"2014","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.jare.2025.02.006_b0065","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1038\/s41409-023-01989-3","article-title":"Prognostic factors and clinical outcomes in patients with relapsed acute leukemia after allogeneic hematopoietic stem cell transplantation","volume":"58","author":"Gao","year":"2023","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"10.1016\/j.jare.2025.02.006_b0070","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.bbmt.2015.09.001","article-title":"International, multicenter standardization of acute graft-versus-host disease clinical data collection: a report from the mount Sinai acute GVHD international consortium","volume":"22","author":"Harris","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"10.1016\/j.jare.2025.02.006_b0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbmt.2014.12.001","article-title":"National institutes of health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. The 2014 Diagnosis and Staging Working Group report","volume":"21","author":"Jagasia","year":"2015","journal-title":"Biol Blood Marrow Transplantation: J American Soc Blood Marrow Transplant"},{"issue":"4","key":"10.1016\/j.jare.2025.02.006_b0080","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1038\/bmt.2015.305","article-title":"Definition of GvHD-free, relapse-free survival for registry-based studies: an ALWP-EBMT analysis on patients with AML in remission","volume":"51","author":"Ruggeri","year":"2016","journal-title":"Bone Marrow Transplant"},{"issue":"4","key":"10.1016\/j.jare.2025.02.006_b0085","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1038\/sj.bmt.1705727","article-title":"Competing risk analysis using R: an easy guide for clinicians","volume":"40","author":"Scrucca","year":"2007","journal-title":"Bone Marrow Transplant"},{"issue":"10","key":"10.1016\/j.jare.2025.02.006_b0090","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1002\/ajh.25582","article-title":"Anti-CD19 chimeric antigen receptor-modified T-cell therapy bridging to allogeneic hematopoietic stem cell transplantation for relapsed\/refractory B-cell acute lymphoblastic leukemia: an open-label pragmatic clinical trial","volume":"94","author":"Jiang","year":"2019","journal-title":"Am J Hematol"},{"issue":"1","key":"10.1016\/j.jare.2025.02.006_b0095","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/s41409-020-0982-6","article-title":"Allogeneic haematopoietic stem cell transplantation improves outcome of adults with relapsed\/refractory Philadelphia chromosome-positive acute lymphoblastic leukemia entering remission following CD19 chimeric antigen receptor T cells","volume":"56","author":"Gu","year":"2021","journal-title":"Bone Marrow Transplant"},{"issue":"11","key":"10.1016\/j.jare.2025.02.006_b0100","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.1038\/s41409-020-0926-1","article-title":"Low toxicity and favorable overall survival in relapsed\/refractory B-ALL following CAR T cells and CD34-selected T-cell depleted allogeneic hematopoietic cell transplant","volume":"55","author":"Fabrizio","year":"2020","journal-title":"Bone Marrow Transpl"},{"issue":"20","key":"10.1016\/j.jare.2025.02.006_b0105","doi-asserted-by":"crossref","first-page":"3062","DOI":"10.1182\/bloodadvances.2019000593","article-title":"Safety of allogeneic hematopoietic cell transplant in adults after CD19-targeted CAR T-cell therapy","volume":"3","author":"Shadman","year":"2019","journal-title":"Blood Adv"},{"key":"10.1016\/j.jare.2025.02.006_b0110","article-title":"Integrating CAR T-cell therapy and transplantation: comparisons of safety and long-term efficacy of allogeneic hematopoietic stem cell transplantation After CAR T-cell or chemotherapy-based complete remission in B-cell acute lymphoblastic leukemia","volume":"12","author":"Zhao","year":"2021","journal-title":"Front Immunol"},{"issue":"13","key":"10.1016\/j.jare.2025.02.006_b0115","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2024.e33937","article-title":"CD19 chimeric antigen receptor-T cells as bridging therapy to allogeneic hematopoietic cell transplantation improves outcome in patients with refractory\/relapsed B-cell acute lymphoblastic leukemia","volume":"10","author":"Liu","year":"2024","journal-title":"Heliyon"},{"issue":"3","key":"10.1016\/j.jare.2025.02.006_b0120","first-page":"239","article-title":"Safety and efficacy of patients with refractory B-lymphoblastic leukemia treated with anti-CD19 CAR-T cell bridging to allogeneic hematopoietic stem cell transplantation","volume":"41","author":"Ai","year":"2020","journal-title":"Zhonghua Xue Ye Xue Za Zhi = Zhonghua Xueyexue Zazhi"},{"key":"10.1016\/j.jare.2025.02.006_b0125","doi-asserted-by":"crossref","DOI":"10.1038\/s41409-024-02300-8","article-title":"Prognostic factors impacting post-transplant outcomes in adult T-cell acute lymphoblastic leukemia: a registry-based study by the EBMT acute leukemia working party","author":"El Cheikh","year":"2024","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"10.1016\/j.jare.2025.02.006_b0130","doi-asserted-by":"crossref","first-page":"e185","DOI":"10.1016\/S2352-3026(20)30429-4","article-title":"Clinical characteristics and outcomes of COVID-19 in haematopoietic stem-cell transplantation recipients: an observational cohort study","volume":"8","author":"Sharma","year":"2021","journal-title":"Lancet Haematol"},{"issue":"8","key":"10.1016\/j.jare.2025.02.006_b0135","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1182\/blood-2009-10-247510","article-title":"Transplantation of allogeneic hematopoietic stem cells for adult T-cell leukemia: a nationwide retrospective study","volume":"116","author":"Hishizawa","year":"2010","journal-title":"Blood"}],"container-title":["Journal of Advanced Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2090123225000785?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2090123225000785?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,18]],"date-time":"2026-01-18T15:28:59Z","timestamp":1768750139000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2090123225000785"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":27,"alternative-id":["S2090123225000785"],"URL":"https:\/\/doi.org\/10.1016\/j.jare.2025.02.006","relation":{},"ISSN":["2090-1232"],"issn-type":[{"value":"2090-1232","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Sequential allogeneic HSCT after CAR-T therapy for relapsed\/refractory acute lymphoblastic leukemia patients: A long-term follow-up result","name":"articletitle","label":"Article Title"},{"value":"Journal of Advanced Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jare.2025.02.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier B.V. on behalf of Cairo University.","name":"copyright","label":"Copyright"}]}}